Overview
Synthetic analogue of growth hormone-releasing hormone (GHRH) with extended half-life. Often used in combination with Ipamorelin.
Key Specifications
| Category | GHRH Analogue |
| FDA Status | Category 1 (2026) |
| Purity Benchmark | ≥98% HPLC |
| Applications | Growth hormone research, body composition optimization |
Sourcing Notes
When sourcing CJC-1295, verify the following with any supplier: batch-specific COA with HPLC purity data, LC-MS identity confirmation showing the expected molecular weight, endotoxin testing results if the material will be used for injectable formulations, and storage/stability specifications appropriate for your intended use.
For a complete guide to COA verification, see our COA Verification Guide.
Get the Korea Bridge Sourcing Protocol
Free 38-page editorial playbook on regulatory navigation, supplier diligence, and the 12-point red flag checklist for licensed peptide procurement teams.
Get the Protocol →